Speedboat™ Inject selected by NICE for assessment

Creo Medical Group PLC

01 June 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Speedboat™ Inject selected by NICE for assessment

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that the National Institute for Health and Care Excellence ("NICE") has selected Speedboat Inject to be scoped and routed for guidance in respect of the endoscopic submucosal dissection ("ESD") of lower gastrointestinal ("GI") lesions. 

This selection follows a committee review of headline data and initiates a multi-step process whereby Speedboat's lower GI ESD clinical and economic evidence, along with other data, is evaluated by NICE and, if appropriate, may result in a specific NICE output such as Medical Technologies Guidance.

NICE selected Speedboat Inject for scoping and routing because it "anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources".

More information on Speedboat's guidance development can be found here.

Craig Gulliford, CEO of Creo Medical, said: "We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK. We look forward to the outcome of the final stages of the review process as NICE concludes its work."

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Numis Securities Limited (Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown	[phone]
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.  CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END